These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23993306)

  • 1. A simple quantitative diagnostic alternative for MGMT DNA-methylation testing on RCL2 fixed paraffin embedded tumors using restriction coupled qPCR.
    Pulverer W; Hofner M; Preusser M; Dirnberger E; Hainfellner JA; Weinhaeusel A
    Clin Neuropathol; 2014; 33(1):50-60. PubMed ID: 23993306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confounding factors in diagnostics of MGMT promoter methylation status in glioblastomas in stereotactic biopsies.
    Weise LM; Harter PN; Eibach S; Braczynski AK; Dunst M; Rieger J; Bähr O; Hattingen E; Steinbach JP; Plate KH; Seifert V; Mittelbronn M
    Stereotact Funct Neurosurg; 2014; 92(3):129-39. PubMed ID: 24776650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging.
    Drabycz S; Roldán G; de Robles P; Adler D; McIntyre JB; Magliocco AM; Cairncross JG; Mitchell JR
    Neuroimage; 2010 Jan; 49(2):1398-405. PubMed ID: 19796694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis.
    Mikeska T; Bock C; El-Maarri O; Hübner A; Ehrentraut D; Schramm J; Felsberg J; Kahl P; Büttner R; Pietsch T; Waha A
    J Mol Diagn; 2007 Jul; 9(3):368-81. PubMed ID: 17591937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reliability and reproducibility of PCR-based testing of O6-methylguanine-DNA methyltransferase gene (MGMT) promoter methylation status in formalin-fixed and paraffin-embedded neurosurgical biopsy specimens.
    Preusser M; Elezi L; Hainfellner JA
    Clin Neuropathol; 2008; 27(6):388-90. PubMed ID: 19130735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma.
    Preusser M; Berghoff AS; Manzl C; Filipits M; Weinhäusel A; Pulverer W; Dieckmann K; Widhalm G; Wöhrer A; Knosp E; Marosi C; Hainfellner JA
    Clin Neuropathol; 2014; 33(1):6-14. PubMed ID: 24359605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme.
    Limam S; Missaoui N; Abdessayed N; Mestiri S; Selmi B; Mokni M; Yacoubi MT
    Ann Biol Clin (Paris); 2019 Jun; 77(3):307-317. PubMed ID: 31131831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of the methylation status of MGMT in different regions within glioblastoma multiforme.
    Hamilton MG; Roldán G; Magliocco A; McIntyre JB; Parney I; Easaw JC
    J Neurooncol; 2011 Apr; 102(2):255-60. PubMed ID: 20652362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas.
    Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H
    Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.
    Xie H; Tubbs R; Yang B
    Int J Clin Exp Pathol; 2015; 8(2):1790-6. PubMed ID: 25973069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural and advanced imaging in predicting MGMT promoter methylation of primary glioblastoma: a region of interest based analysis.
    Han Y; Yan LF; Wang XB; Sun YZ; Zhang X; Liu ZC; Nan HY; Hu YC; Yang Y; Zhang J; Yu Y; Sun Q; Tian Q; Hu B; Xiao G; Wang W; Cui GB
    BMC Cancer; 2018 Feb; 18(1):215. PubMed ID: 29467012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGMT promoter methylation and glioblastoma: a comparison of analytical methods and of tumor specimens.
    Lattanzio L; Borgognone M; Mocellini C; Giordano F; Favata E; Fasano G; Vivenza D; Monteverde M; Tonissi F; Ghiglia A; Fillini C; Bernucci C; Merlano M; Lo Nigro C
    Int J Biol Markers; 2015 May; 30(2):e208-16. PubMed ID: 25588856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixation of brain tumor biopsy specimens with RCL2 results in well-preserved histomorphology, immunohistochemistry and nucleic acids.
    Preusser M; Plumer S; Dirnberger E; Hainfellner JA; Mannhalter C
    Brain Pathol; 2010 Nov; 20(6):1010-20. PubMed ID: 20477829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of MGMT promoter methylation in glioblastoma using pyrosequencing.
    Xie H; Tubbs R; Yang B
    Int J Clin Exp Pathol; 2015; 8(1):636-42. PubMed ID: 25755756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MethylMeter(®): bisulfite-free quantitative and sensitive DNA methylation profiling and mutation detection in FFPE samples.
    McCarthy D; Pulverer W; Weinhaeusel A; Diago OR; Hogan DJ; Ostertag D; Hanna MM
    Epigenomics; 2016 Jun; 8(6):747-65. PubMed ID: 27337298
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MGMT expression and promoter methylation status may depend on the site of surgical sample collection within glioblastoma: a possible pitfall in stratification of patients?
    Della Puppa A; Persano L; Masi G; Rampazzo E; Sinigaglia A; Pistollato F; Denaro L; Barzon L; Palù G; Basso G; Scienza R; d'Avella D
    J Neurooncol; 2012 Jan; 106(1):33-41. PubMed ID: 21725802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin.
    Park CK; Park SH; Lee SH; Kim CY; Kim DW; Paek SH; Kim DG; Heo DS; Kim IH; Jung HW
    Neuropathology; 2009 Aug; 29(4):443-9. PubMed ID: 19170894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Learning MRI-based classification models for MGMT methylation status prediction in glioblastoma.
    Kanas VG; Zacharaki EI; Thomas GA; Zinn PO; Megalooikonomou V; Colen RR
    Comput Methods Programs Biomed; 2017 Mar; 140():249-257. PubMed ID: 28254081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.
    Quillien V; Lavenu A; Ducray F; Joly MO; Chinot O; Fina F; Sanson M; Carpentier C; Karayan-Tapon L; Rivet P; Entz-Werle N; Legrain M; Zalcman EL; Levallet G; Escande F; Ramirez C; Chiforeanu D; Vauleon E; Figarella-Branger D
    Oncotarget; 2016 Sep; 7(38):61916-61929. PubMed ID: 27542245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.
    Ellingson BM; Cloughesy TF; Pope WB; Zaw TM; Phillips H; Lalezari S; Nghiemphu PL; Ibrahim H; Naeini KM; Harris RJ; Lai A
    Neuroimage; 2012 Jan; 59(2):908-16. PubMed ID: 22001163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.